UCB’s Rystiggo Becomes Second FcRn Inhibitor Treatment For gMG
Following FDA Approval
The Belgian firm’s Rystiggo may be the second drug of its class to win approval, but a broad label encompassing two major patient groups in generalized myasthenia gravis could set it apart as work starts for a launch later this year.
